MedPath

Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)

Active, not recruiting
Conditions
Multiple Sclerosis
Interventions
Registration Number
NCT04934800
Lead Sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Brief Summary

The main aim is to study in the real world setting the effectiveness of Cladribine tablets in terms of Annualized Relapse Rate (ARR) and disability progression, in participants who switched from a first line Disease Modifying Drug (DMD) (Interferons, Glatiramer Acetate, Teriflunomide, (Dymethyl fumarate) \[DMF\]) to treatment with Cladribine tablets in routine clinical practice.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
256
Inclusion Criteria
  • Participants with confirmed diagnosis of RRMS diagnosed by the treating physician according to applicable clinical practice guidelines -(currently McDonald 2017 criteria), with high disease activity
  • Participants should have been treated with the same first-line DMD (Interferons, Glatiramer Acetate, Teriflunomide, DMF) and at a stable dose for at least one year prior to switch to Cladribine tablets and should have been prescribed Cladribine tablets, according to the decision of the treating physician, prior to enrollment in the study. Any washout period and/or washout methods required before switching (such as elimination of Teriflunomide) must have been conducted, according to the decision of the treating physician
  • Required history data should be available: Multiple Sclerosis (MS) data for the 12-months pre-baseline period (annualized relapse rate); MS Medication History (prior DMDs)
  • Fulfilment of the criteria for treatment with Cladribine tablets per standard of care in accordance with the local Summary of Product Characteristics (SmPC)
Read More
Exclusion Criteria
  • Contraindications to use of cladribine tablets according to the SmPC
  • Participants with history of alcohol or drug abuse that could potentially interfere with their participation in the study
  • Participants that have received Cladribine in the past
  • Concurrent participation in an investigational study in which participant assessment and/or treatment may be dictated by a protocol
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
CladribineCladribine-
Primary Outcome Measures
NameTimeMethod
Change in Annualized Relapse Rate (ARR) Between the Pre-Baseline 12-Month Period Over the 12 Months Period Before the End of Study Follow-Up12-months pre-baseline up to Year 2 post-baseline
Secondary Outcome Measures
NameTimeMethod
Percentage of Participants with 6-Month Disability Progression in Expanded Disability Status Scale (EDSS)Up to 2 years
Percentage of Participants with 6-Month Disability Progression in 9-Hole-Peg Test (9HPT)Up to 2 years
Percentage of Participants with 6-Month Disability Improvement in Expanded Disability Status Scale (EDSS)Up to 2 years
Percentage of Participants with 6-Month Disability Improvement in Timed 25 Foot Walk (T25FW)Up to 2 years
Quality of Life Assessed by Multiple Sclerosis Impact Scale (MSIS-29)Baseline, Months 12 and 24
Percentage of Participants with 6-Month Disability Progression in Timed 25 Foot Walk (T25FW)Up to 2 years
Percentage of Participants with 6-Month Disability Improvement in 9-Hole-Peg Test (9HPT)Up to 2 years
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Up to 2 years
Treatment Satisfaction Assessed by Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM v1.4) ScaleMonths 6, 12, 18 and 24
Pharmacoeconomic Data Assessed by Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) QuestionnaireBaseline, Months 12 and 24
Percentage of Participants With Treatment AdherenceUp to Month 24
Change in Annualized Relapse Rate (ARR) Between the Pre-Baseline 12-Month Period Over the 12 Months Period After the Start of Cladribine12-months pre-baseline up to Year 1 post-baseline

Trial Locations

Locations (61)

Papageorgiou General Hospital Thessaloniki

🇬🇷

Thessaloniki, Greece

University General Hospital of Patra

🇬🇷

Patras, Greece

General Hospital of Patra "Agios Andreas"

🇬🇷

Patra, Greece

AHEPA General Hospital of Thessaloniki

🇬🇷

Thessaloniki, Greece

General Hospital of Thessaloniki "G. Papanikolaou"

🇬🇷

Thessaloniki, Greece

Interbalkan Hospital of Thessaloniki

🇬🇷

Thessaloniki, Greece

St Luke's Hospital

🇬🇷

Thessaloniki, Greece

Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII) - Dipartimento di Neurologia

🇮🇹

Bergamo, Italy

Fondazione Istituto G.Giglio di Cefalù - Neurologia-Centro Sclerosi Multipla

🇮🇹

Cefalù, Italy

Università degli Studi G. D'Annunzio

🇮🇹

Chieti, Italy

Azienda Ospedaliera Universitaria Arcispedale Sant'Anna - Neurologia

🇮🇹

Cona, Italy

Ospedali Riuniti di Foggia - Neurology

🇮🇹

Foggia, Italy

Azienda Socio Sanitaria Territoriale della Valle Olona (presidio di Gallarate) - Neurologia 2 - Sclerosi Multipla

🇮🇹

Gallarate, Italy

ASL 1 Avezzano L'Aquila Sulmona- Ospedale Regionale San Salvatore - Dipartimento di Neurologia

🇮🇹

L'Aquila, Italy

IRCCS Centro Neurolesi Bonino Pulejo - U.O. di Neurofisipatologia ed Ambulatori

🇮🇹

Messina, Italy

Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli - U.O.S. Malattie Degenerative del S.N.C.

🇮🇹

Napoli, Italy

Grande Ospedale Metropolitano "Bianchi Melacrino Morelli - Centro Regionale Epilessia

🇮🇹

Reggio Calabria, Italy

Ospedale Maggiore della carità - Novara

🇮🇹

Novara, Italy

Centro di Riferimento Regionale per la Sclerosi Multipla (CRESM) - SCDO Neurologia

🇮🇹

Orbassano, Italy

Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone - Dipartimento di Neuroscienze

🇮🇹

Palermo, Italy

Azienda Ospedaliera di Udine Ospedale S. Maria della Misericordia - UO Neurologia

🇮🇹

Perugia, Italy

Azienda Ospedaliera San Filippo Neri - Neurologia

🇮🇹

Roma, Italy

Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza - Dip. di Neurologia e Psichiatria (servizio EMG)

🇮🇹

Roma, Italy

KH der Barmherzige Brüder Eisenstadt - Neurology

🇦🇹

Eisenstadt, Austria

Dr. Reinhard Krendl-Head

🇦🇹

Sankt Veit an der Glan, Austria

Klinik Florisdorf

🇦🇹

Wien, Austria

University of Ioannina - Neurology Department, Ioannina

🇬🇷

Ioannina, Greece

Iatriko Palaioy Faliroy, Medical Center - Neurology Department

🇬🇷

Paleo Faliro, Greece

Ospedale San Luca - S.C.Oncologia

🇮🇹

Lucca, Italy

Pomorski Uniwersytet Medyczny - Klinika Neurologii

🇵🇱

Szczecin, Poland

Luzerner Kantonsspital - Zentrum fuer Neurologie und Neurorehabilitation

🇨🇭

Luzern 16, Switzerland

University of Thrace, Medical School - Neurology Department

🇬🇷

Alexandroupolis, Greece

251 General Air Force Hospital

🇬🇷

Athens, Greece

417 NIMITS Hospital

🇬🇷

Athens, Greece

Aeginiteion Hospital, University of Athens - A' Neurology Department

🇬🇷

Athens, Greece

Attikon University Hospital

🇬🇷

Athens, Greece

Evangelismos Hospital - Neurology Department

🇬🇷

Athens, Greece

Genaral Hospital of Elefsina "Thriasio"

🇬🇷

Athens, Greece

General Hospital of Athens "Evangelismos"

🇬🇷

Athens, Greece

University General Hospital of Larissa - Rheumatology Clinic

🇬🇷

Larissa, Greece

A. O. U. San Giovanni Di Dio e Ruggi D'Aragona - Struttura Complessa di Oculistica

🇮🇹

Salerno, Italy

Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma) - D.U.Neurologia

🇮🇹

Verona, Italy

Vestre Viken HF Drammen Sykehus - former Sykehuset Buskerud

🇳🇴

Drammen, Norway

Sykehuset Namsos

🇳🇴

Namsos, Norway

Oslo Universitetssykehus HF - Ullevål

🇳🇴

Oslo, Norway

Uniwersytecki Szpital Kliniczny w Bialymstoku - Dept of Neurology

🇵🇱

Bialystok, Poland

Szpital Specjalistyczny im. L.Rydygiera w Krakowie - Neurology Department

🇵🇱

Krakow, Poland

Szpital Uniwersytecki w Krakowie - Uniwersytet Jagiellonski Collegium Medicum

🇵🇱

Krakow, Poland

Szpital Kliniczny im.Heliodora Swiecickiego Uniwersytetu Medycznego im.K. Marcinkowskiego w Poznaniu - Dept of Neurology

🇵🇱

Poznan, Poland

Wojskowy Instytut Medyczny - Klinika Neurologiczna

🇵🇱

Warszawa, Poland

SPZOZ Wojewodzki Szpital Specjalistyczny nr 3 w Rybniku

🇵🇱

Zory, Poland

Centro Hospitalar de Lisboa Ocidental, E.P.E. - Hospital de Egas Moniz - Serviço de Neurologia

🇵🇹

Lisboa, Portugal

Unidade Local de Saúde de Matosinhos, EPE (Hospital Pedro Hispano) - Serviço de Neurologia

🇵🇹

Matosinhos, Portugal

Centro Hospitalar de São João, E.P.E. - Serviço de Neurologia

🇵🇹

Porto, Portugal

Hospital Garcia de Orta, EPE - Serviço de Neurologia

🇵🇹

Pragal, Portugal

Centro Hospitalar de Setubal, EPE - Hospital São Bernardo

🇵🇹

Setúbal, Portugal

Unidade Local de Saúde do Alto Minho, EPE - Serviço de Neurologia

🇵🇹

Viana De Castelo, Portugal

Inselspital - Universitaetsspital Bern - Neuropsychologische Rehabilitation, Neurologie

🇨🇭

Bern, Switzerland

(CHUV), Centre Hospitalier Universitaire Vaudois - Departement des Neurosciences Cliniques

🇨🇭

Lausanne, Switzerland

Ospedale Regionale di Lugano - Neurologia

🇨🇭

Lugano, Switzerland

Hôpital Régional Sion-Hérens-Conthey - Neurologie

🇨🇭

Sion, Switzerland

© Copyright 2025. All Rights Reserved by MedPath